CHU De Rouen

Futó vizsgálatok

• Toboroz

  Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI

  NCT06501482· 3. fázis· Forrás

• Toboroz

  JAK Inhibitor Dose TAPering Strategy Study

  NCT06687551· 4. fázis· Forrás

• Toboroz

  Intra-Arterial Thrombolysis After SUCCESSful Reperfusion in Anterior Circulation Ischemic Stroke

  NCT06768138· 3. fázis· Forrás

• Toboroz

  Beta-blOckers discoNtinuation in patients presenting heart FaIlure with REcovered left ventricular ejection fraction

  2023-508798-94-00· 3. fázis· Forrás

• Toboroz

  PRODIGE 90 - FFCD 22024 - PREDIR-NEOREC - Neoadjuvant dostarlimab with short course radiotherapy in a watch-and-wait strategy for microsatellite unstable or mismatch repair-deficient locally advanced rectal cancer patients: a randomized phase II trial

  2024-510772-20-00· 2. fázis· Forrás

• Toboroz

  Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC

  NCT06552234· 2. fázis· Forrás

• Fut, nem toboroz

  A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

  NCT06238622· 3. fázis· Forrás

• Toboroz

  Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

  NCT06496581· 3. fázis· Forrás

• Toboroz

  Immunotherapy with dostarlimab for locally advanced or metastatic cancer (non-colorectal/non-endometrial) with tumor dMMR/MSI

  2023-505298-34-00· 2. fázis· Forrás

• Fut, nem toboroz

  A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

  NCT06407934· 3. fázis· Forrás

• Toboroz

  A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

  NCT06312137· 3. fázis· Forrás

• Toboroz

  DOR/TDF/3TC Switch With M184V/I in People With Controlled HIV (Drive Off-Road)

  NCT06034938· 2. fázis· Forrás

• Fut, nem toboroz

  A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

  NCT06140836· 3. fázis· Forrás

• Fut, nem toboroz

  A study to investigate the efficacy and safety of tezepelumab compared with placebo in children 5 to < 12 years old with severe asthma

  2022-502984-39-00· 3. fázis· Forrás

• Toboroz

  A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

  NCT05920356· 3. fázis· Forrás

• Fut, nem toboroz

  Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

  NCT06074588· 3. fázis· Forrás

• Fut, nem toboroz

  MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

  NCT06097728· 3. fázis· Forrás

• Fut, nem toboroz

  Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

  NCT06087835· 3. fázis· Forrás

• Toboroz

  Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

  NCT05980949· 3. fázis· Forrás

• Toboroz

  Tranexamic acid for hyperacute spontaneous IntraCerebral Haemorrhage (TICH-3)

  2022-500587-35-01· 3. fázis· Forrás

• Toboroz

  RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.

  NCT05758831· 3. fázis· Forrás

• Fut, nem toboroz

  Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy

  NCT05781308· 2. fázis· Forrás

• Fut, nem toboroz

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· 3. fázis· Forrás

• Toboroz

  Intensification of Blood Pressure Lowering Therapeutics Based on Diuretics Versus Usual Management for Uncontrolled Hypertension IN Patients With Moderate to Severe Chronic Kidney Disease

  NCT05732727· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

  NCT05625399· 3. fázis· Forrás

• Fut, nem toboroz

  A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

  NCT05608291· 3. fázis· Forrás

• Fut, nem toboroz

  Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

  NCT05687266· 3. fázis· Forrás

• Toboroz

  Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia

  NCT05327894· 3. fázis· Forrás

• Toboroz

  Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)

  NCT05384821· 1/2. fázis· Forrás

• Fut, nem toboroz

  A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

  NCT05399888· 2. fázis· Forrás

• Toboroz

  Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab

  NCT05303532· 3. fázis· Forrás

• Fut, nem toboroz

  Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)

  NCT05200481· 2. fázis· Forrás

• Toboroz

  Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy

  NCT05180825· 2. fázis· Forrás

• Fut, nem toboroz

  A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

  NCT05221840· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

  NCT04819100· 3. fázis· Forrás

• Toboroz

  Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET

  NCT04954820· 2. fázis· Forrás

• Fut, nem toboroz

  Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients)

  NCT01817192· 4. fázis· Forrás

• Toboroz

  A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

  NCT04307576· 3. fázis· Forrás

• Toboroz

  International study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastine

  2022-501454-11-00· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

  NCT04025879· 3. fázis· Forrás

• Meghívásos bevonás

  A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

  NCT03683186· 3. fázis· Forrás

• Toboroz

  Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer

  NCT03875781· 3. fázis· Forrás

• Fut, nem toboroz

  A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

  NCT03568318· 3. fázis· Forrás

• Fut, nem toboroz

  Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease

  NCT03323476· 3. fázis· Forrás

• Lezárult

  Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients

  NCT02980510· 2. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Gyermekkori daganatok6 toboroz
• Tüdőrák4 toboroz
• Vastagbélrák3 toboroz
• Akut limfoid leukémia (ALL)2 toboroz
• Stroke (szélütés)2 toboroz
• Alzheimer-kór1 toboroz
• HIV-fertőzés1 toboroz
• Hólyagrák1 toboroz
• Krónikus vesebetegség1 toboroz
• Magas vérnyomás1 toboroz
• Méhtestrák1 toboroz
• Melanóma1 toboroz
• Neuroendokrin daganatok1 toboroz
• Prosztatarák1 toboroz
• Rheumatoid arthritis1 toboroz
• Szívelégtelenség1 toboroz
• Vesedaganat1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  Phase 2 study to evaluate the efficacy and safety of GSK3915393 in participants with Idiopathic Pulmonary Fibrosis (IPF)

  NCT06317285· 2. fázis· Forrás

• Lezárult

  Effects of maintenance cabozantinib+BSC versus BSC in children and AYA with osteosarcoma. ( CabOSTar )

  NCT06341712· 2. fázis· Forrás

• Lezárult

  A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

  NCT06238817· 3. fázis· Forrás

• Lezárult

  A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)

  NCT05865886· 2. fázis· Forrás

• Lezárult

  A Clinical Study to Compare the Impact of Multiple-dose Oral Administration of Macitentan, 10 mg versus 75 mg on Endothelin-1 Clearance, Endothelial Function, and Hemodynamics in Healthy Participants

  2023-504643-13-00· 1. fázis· Forrás

• Lezárult

  A proof of concept and dose-finding study of XXB750 in patients with heart failure

  2023-504678-39-00· 2. fázis· Forrás

• Fut, nem toboroz

  A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

  NCT06241118· 3. fázis· Forrás

• Fut, nem toboroz

  A Study to Evaluate ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Unresectable or Metastatic Melanoma

  2023-503288-40-00· 3. fázis· Forrás

• Toboroz

  A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

  2023-505121-14-00· 3. fázis· Forrás

• Lezárult

  A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids

  NCT06224348· 3. fázis· Forrás

• Lezárult

  A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

  NCT06108544· 3. fázis· Forrás

• Lezárult

  A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD (ROCKET-ASCEND)

  NCT05882877· 3. fázis· Forrás

• Lezárult

  A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis

  NCT05923099· 2. fázis· Forrás

• Lezárult

  A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy

  NCT05958407· 3. fázis· Forrás

• Lezárult

  An 18-month study to assess joint outcomes in patients with haemophilia A or B on prophylaxis with efmoroctocog alfa or eftrenonacog alfa

  2022-502921-16-00· 4. fázis· Forrás

• Lezárult

  A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

  NCT05877547· 2. fázis· Forrás

• Lezárult

  Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

  NCT05814627· 3. fázis· Forrás

• Lezárult

  A study to assess efficacy and safety of benralizumab in paediatric patients with severe eosinophilic asthma (severe asthma marked by high level of a type of white blood cells - eosinophils)

  2022-501344-14-00· 3. fázis· Forrás

• Fut, nem toboroz

  Premedication to Reduce Amivantamab Associated Infusion Related Reactions

  NCT05663866· 2. fázis· Forrás

• Lezárult

  Phase 3, 52-week Study Evaluating Rocatinlimab (AMG451)in Adolescent Subjects With Moderate-to-severe AD (ROCKET-ASTRO)

  2022-501586-50-00· 3. fázis· Forrás

• Lezárult

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· 3. fázis· Forrás

• Fut, nem toboroz

  A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis

  NCT05785611· 3. fázis· Forrás

• Lezárult

  PRODIGE 81-FFCD 2101-TRIPLET: Study evaluating the benefit of adding Ipilimumab to the combination of Atezolizumab and Bevacizumab in patients with hepatocellular carcinoma receiving first-line systemic therapy-

  2022-501217-31-00· 2/3. fázis· Forrás

• Lezárult

  Dupilumab step-down strategy to maintain remission in adult and adolescents patients with atopic dermatitis: a non-inferiority randomized trial

  2022-501179-23-00· 4. fázis· Forrás

• Lezárult

  A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05724199· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· 3. fázis· Forrás

• Lezárult

  Phase 2 Study of MORAb-202 in Previously Treated Metastatic NSCLC AC

  NCT05577715· 2. fázis· Forrás

• Lezárult

  Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)

  NCT05630820· 3. fázis· Forrás

• Lezárult

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· 3. fázis· Forrás

• Lezárult

  Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102)

  NCT05111626· 3. fázis· Forrás

• Lezárult

  A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)

  NCT05093933· 3. fázis· Forrás

• Lezárult

  A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

  NCT04732221· 2/3. fázis· Forrás

• Lezárult

  A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study with a Long-Term Extension Treatment Period to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants with Early Alzheimer’s Disease

  2022-501188-42-00· 2. fázis· Forrás

• Fut, nem toboroz

  A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

  NCT04544436· 3. fázis· Forrás

• Lezárult

  Management of Progressive Disease in Idiopathic Pulmonary Fibrosis

  NCT03939520· 4. fázis· Forrás

• Lezárult

  Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

  NCT03976323· 3. fázis· Forrás

• Lezárult

  A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)

  NCT03976362· 3. fázis· Forrás

• Lezárult

  Phase 3 study of SBRT ± pembrolizumab for participants with unresectable Stage I or II NSCLC

  NCT03924869· 3. fázis· Forrás

• Lezárult

  Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

  NCT03924856· 3. fázis· Forrás

• Lezárult

  A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

  NCT03626688· 3. fázis· Forrás

• Lezárult

  Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

  NCT03615326· 3. fázis· Forrás

• Lezárult

  Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn's Disease

  2023-510426-33-00· 3. fázis· Forrás

• Lezárult

  Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)

  NCT03569293· 3. fázis· Forrás

• Lezárult

  This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)

  NCT03599245· 3. fázis· Forrás

• Fut, nem toboroz

  Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

  NCT03425643· 3. fázis· Forrás

• Lezárult

  A study of nivolumab or placebo in patients following removal of their esophageal or gastroesophageal junction cancer.

  NCT02743494· 3. fázis· Forrás